Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Verve Therapeutics (VERV – Research Report). The associated price target remains the same with $25.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Verve Therapeutics’ promising developments and financial health. The company recently announced encouraging initial data from its Phase 1 Heart-2 study, which evaluates the PCSK9-targeting base editor, VERVE-102, in patients with specific cardiovascular conditions. The study showed a significant dose-response curve in LDL-C lowering, with reductions comparable to currently approved PCSK9 inhibitors, suggesting potential competitive advantages in efficacy and dosing frequency.
Moreover, the safety profile of VERVE-102 was notably strong, with no treatment-related serious adverse events reported. The company’s financial position is robust, with $497.1 million on the balance sheet, allowing it to pursue key milestones into mid-2027. The upcoming Phase 2 study and potential decisions regarding Eli Lilly’s opt-in package further contribute to the optimistic outlook. These elements together underpin the Buy rating, reflecting confidence in Verve Therapeutics’ future growth potential and strategic direction.